Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Lieber

Pulmonary Disease Tamarac, FL Medical Doctor

NPI 1588676662 CMS profile 298383

6610 N University Dr, Suite 120, Tamarac, FL 33321

Open in the dashboard

General payments

$14,384

714 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charles Lieber of Tamarac, FL is reported in the CMS Open Payments database as having received $14,384 across 714 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,934 85
2024 General $1,420 66
2023 General $2,229 108
2022 General $2,456 120
2021 General $2,291 110
2020 General $1,859 110
2019 General $2,194 115

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Lieber
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Charles Lieber were reported at $1,934. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Charles Lieber Pulmonary Disease median Middle half National median
2019 $2,194 $377 $109–$1,340 $163
2020 $1,859 $230 $56–$907 $114
2021 $2,291 $269 $68–$1,072 $132
2022 $2,456 $390 $100–$1,457 $149
2023 $2,229 $419 $114–$1,659 $160
2024 $1,420 $476 $123–$1,818 $164
2025 $1,934 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $3,490 167 payments
  2. GlaxoSmithKline, LLC. $2,481 131 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,642 99 payments
  4. Mylan Specialty L.P. $628 21 payments
  5. Lilly USA, LLC $487 30 payments
  6. Regeneron Healthcare Solutions, Inc. $463 16 payments
  7. Grifols USA, LLC $442 23 payments
  8. Amarin Pharma Inc. $419 24 payments
  9. Amgen Inc. $398 18 payments
  10. Genzyme Corporation $327 14 payments
  11. Other $3,608 171 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,269 712 payments
  2. Education $115 2 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $1,349 70 payments
  2. FASENRA $991 50 payments
  3. BREZTRI $895 34 payments
  4. TEZSPIRE Respiratory $532 25 payments
  5. JARDIANCE $494 33 payments
  6. SYMBICORT $468 25 payments
  7. DUPIXENT $435 15 payments
  8. STIOLTO RESPIMAT $389 24 payments
  9. TEZSPIRE Inflammation $366 16 payments
  10. YUPELRI $363 14 payments
  11. Other $10,390 543 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 59 drugs

Part D claims

1,949

Median for Pulmonary Disease: 936

Drug cost

$508,016

Median for Pulmonary Disease: $487,987

Branded share of claims

42.6%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 11 $139,839
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 136 $110,601
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 98 $72,173
Mounjaro Tirzepatide Brand 46 $47,667
Breo Ellipta Fluticasone/Vilanterol Brand 37 $26,261
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 32 $23,523
Symbicort Budesonide/Formoterol Fumarate Brand 67 $18,617
Trulicity Dulaglutide Brand 13 $16,348
Ozempic Semaglutide Brand 12 $13,889
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 18 $8,783

The 10 drugs with the highest cost, of 59 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$75,209

Of which drugs: $36

Medicare patients

237

Average age 75

Services billed

1,759

135 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
COPD 41%
Ischemic heart disease 38%
Diabetes 37%
Depression 29%
Chronic kidney disease 26%
Cancer 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
$256 — —
FASENRA
$158 — —
DUPIXENT
$145 — —
TRELEGY ELLIPTA
$135 136 —
YUPELRI
$104 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

714 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record